Single Treatment With FT1050 of an Ex-vivo Modulated Umbilical Cord Blood Unit

Summary

This trial is a prospective, open-label, single-arm trial of the safety of a single FT1050-treated CB unit for hematopoietic reconstitution after a reduced-intensity conditioning regimen for hematologic malignancies. A maximum of 40 eligible adult subjects will be enrolled and treated in the trial at approximately 2-4 centers within the U.S.

Timeline

Start

2012-01

Primary completion

2013-10

Completion

2013-11

Drugs

Indications